BioCentury
ARTICLE | Clinical News

Opko's diabetes therapy meets in Phase IIb

March 29, 2019 8:14 PM UTC

Opko said OPK88003 met the primary endpoint in a Phase IIb trial to treat adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) said it will evaluate strategic options for the design of Phase III trials of the dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist.

In the modified intent-to-treat (mITT) population (n=108), once-weekly subcutaneous OPK88003 significantly reduced mean HbA1c from baseline to week 30 by 1.3% vs. 0.09% for placebo (p<0.0001). A significantly greater proportion of patients who received OPK88003 achieved an HbA1c of ≤6.5% vs. placebo (50% vs. 13.8%, p=0.0008)...

BCIQ Company Profiles

Opko Health Inc.